Phase IIA study in patients with schizophrenia

Study identifier:D0970C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD2624 in Adult Schizophrenia Patients

Medical condition

schizophrenia

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD2624, Olanzapine, Placebo

Sex

All

Actual Enrollment

106

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 May 2008
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Mar 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria